The NHS in England has struck a payment-by-results deal with a pharmaceutical company for the supply of a drug used to treat hepatitis C. It means the manufacturer will only be paid if a patient is successfully cured. The company and the drug have not been named due to commercial confidentiality, but the arrangement was confirmed by NHS England's chief executive, Simon Stevens. In an interview on BBC Radio 4's Today programme, Stevens said that he had spoken directly to the head of GlaxoSmithKline about the deal, which would mean it could pay up to £50m over
The NHS in England has struck a payment-by-results deal with a pharmaceutical company for the supply of a drug used to treat hepatitis C. It means the manufacturer will only be paid if a patient is successfully cured. The company and the drug have not been named due to commercial confidentiality, but the arrangement was confirmed by NHS England's chief executive, Simon Stevens. If the innovative deal works well, it may be introduced for other costly treatments as the NHS seeks to reduce its £15bn ($20.3bn) annual bill for drugs.